AI Engines For more Details: Perplexity Kagi Labs You
Gastric Ulcers: Irsogladine maleate is effective in treating gastric ulcers, which are open sores that develop on the lining of the stomach. It helps promote the healing of ulcers by enhancing the protective mechanisms of the stomach lining and reducing acid secretion.
Gastritis: Gastritis is inflammation of the stomach lining, which can cause symptoms such as abdominal pain, nausea, vomiting, bloating, and indigestion. Irsogladine maleate helps alleviate symptoms of gastritis by reducing inflammation and promoting the healing of the stomach mucosa.
Cytoprotective Effect: Irsogladine maleate exerts a cytoprotective effect on the stomach mucosa, meaning it helps protect the stomach lining from damage caused by various factors such as excess stomach acid, alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), and stress.
Mucus Production: Irsogladine maleate stimulates the production of mucus in the stomach, which forms a protective barrier over the stomach lining and helps prevent damage from gastric acid and other irritants.
Enhanced Blood Flow: By improving blood flow to the stomach mucosa, irsogladine maleate promotes tissue repair and regeneration, aiding in the healing of gastric ulcers and gastritis.
Symptom Relief: Patients taking irsogladine maleate typically experience relief from symptoms such as abdominal pain, discomfort, and indigestion associated with gastric ulcers and gastritis.
Mode of Action: Irsogladine maleate works by inhibiting the activity of certain enzymes involved in gastric acid secretion, such as histamine H2 receptors and proton pump ATPase. By reducing acid production, it helps create a less acidic environment in the stomach, which is conducive to ulcer healing and symptom relief.
Dosage Forms: Irsogladine maleate is available in various dosage forms, including tablets, capsules, and oral suspensions. The dosage and frequency of administration may vary depending on the severity of the condition being treated and the patient's response to treatment.
Side Effects: Common side effects of irsogladine maleate may include diarrhea, abdominal discomfort, nausea, and headache. These side effects are usually mild and transient.
Contraindications: Irsogladine maleate is contraindicated in individuals with a known hypersensitivity to the medication or any of its components. It should be used with caution in patients with severe liver or kidney impairment.
Drug Interactions: Irsogladine maleate may interact with certain medications, such as antacids, H2-receptor antagonists, and proton pump inhibitors, potentially affecting their absorption or efficacy. Patients should inform their healthcare provider about all medications they are taking before starting irsogladine maleate therapy.
Pregnancy and Lactation: The safety of irsogladine maleate during pregnancy and lactation has not been established. Pregnant or breastfeeding women should consult their healthcare provider before using this medication.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Shigella | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 0 | 1 | Shigella dysenteriae | species | Decreases |
| 0 | 1 | Shigella flexneri | species | Decreases |
| 0 | 1 | Escherichia albertii | species | Decreases |
| 0 | 1 | Bacteroides sp. CACC 737 | species | Decreases |
| 0 | 1 | Escherichia fergusonii | species | Decreases |
| 0 | 1 | Bacteroides sp. A1C1 | species | Decreases |
| 0 | 1 | Shigella boydii | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
| 0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
| 0 | 1 | Bacteroides sp. HF-162 | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 0.6 | 0.6 | |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.7 | -0.17 |
| Allergies | 1 | 0.2 | 4 |
| Allergy to milk products | 0.5 | 0.3 | 0.67 |
| Alzheimer's disease | 1.2 | 1.4 | -0.17 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.4 | 0.75 |
| Ankylosing spondylitis | 0.8 | 0.4 | 1 |
| Anorexia Nervosa | 0.1 | 0.7 | -6 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.9 | 0.2 | 3.5 |
| Atherosclerosis | 0.8 | 0 | 0 |
| Atrial fibrillation | 0.7 | 0.7 | 0 |
| Autism | 1.9 | 2.2 | -0.16 |
| Autoimmune Disease | 0.4 | 0.4 | |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0.3 | 0.1 | 2 |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 0.4 | 0.4 | |
| Brain Trauma | 0.1 | 0.1 | 0 |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.5 | -0.5 | |
| Carcinoma | 0.3 | 0.1 | 2 |
| Celiac Disease | 1.5 | 0.1 | 14 |
| Cerebral Palsy | 0.2 | 0.1 | 1 |
| Chronic Fatigue Syndrome | 1.4 | 1.2 | 0.17 |
| Chronic Kidney Disease | 0.8 | 0.4 | 1 |
| Chronic Lyme | 0.1 | 0.1 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.7 | 0.1 | 6 |
| Chronic Urticaria (Hives) | 0.6 | 0.4 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.1 | 6 |
| Cognitive Function | 0.2 | 0.1 | 1 |
| Colorectal Cancer | 2.7 | 0.9 | 2 |
| Constipation | 1 | 1 | |
| Coronary artery disease | 1.1 | 0.8 | 0.38 |
| COVID-19 | 2 | 2.3 | -0.15 |
| Crohn's Disease | 2.6 | 0.8 | 2.25 |
| Cushing's Syndrome (hypercortisolism) | 0.8 | -0.8 | |
| cystic fibrosis | 0.5 | 0.1 | 4 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1 | 0.2 | 4 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 3 | 1.5 | 1 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.6 | 0.5 | 0.2 |
| Endometriosis | 0.8 | 0.3 | 1.67 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 1.2 | 0.2 | 5 |
| erectile dysfunction | 0.4 | 0.4 | |
| Fibromyalgia | 0.5 | -0.5 | |
| Functional constipation / chronic idiopathic constipation | 1.8 | 0.6 | 2 |
| gallstone disease (gsd) | 1.1 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.1 | 9 |
| Generalized anxiety disorder | 1.1 | 0.2 | 4.5 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.4 | 0.1 | 3 |
| Graves' disease | 0.1 | 0.2 | -1 |
| Gulf War Syndrome | 0.1 | 0.5 | -4 |
| Halitosis | 0.2 | 0.1 | 1 |
| Hashimoto's thyroiditis | 0.5 | 0.2 | 1.5 |
| Heart Failure | 1.1 | 0.4 | 1.75 |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| High Histamine/low DAO | 0.3 | 0.3 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0 | 0 |
| hyperglycemia | 0.7 | 0.2 | 2.5 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 0.5 | 0.6 | -0.2 |
| Hypothyroidism | 0 | 0 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.2 | 0.7 | -2.5 |
| Inflammatory Bowel Disease | 2.3 | 1.4 | 0.64 |
| Insomnia | 0.2 | 0.4 | -1 |
| Intelligence | 0.8 | 0.8 | |
| Intracranial aneurysms | 0.1 | 0.1 | |
| Irritable Bowel Syndrome | 1.4 | 1.3 | 0.08 |
| ischemic stroke | 0.5 | 0.6 | -0.2 |
| Liver Cirrhosis | 1.3 | 0.6 | 1.17 |
| Long COVID | 1.6 | 0.4 | 3 |
| Lung Cancer | 0.4 | 0 | 0 |
| Lymphoma | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.4 | 0.4 | |
| ME/CFS with IBS | 0.1 | 0.1 | 0 |
| ME/CFS without IBS | 0.3 | 0.1 | 2 |
| membranous nephropathy | 0.1 | 0.1 | |
| Menopause | 0.1 | 0 | 0 |
| Metabolic Syndrome | 1.5 | 1.6 | -0.07 |
| Mood Disorders | 2 | 1.5 | 0.33 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 1.4 | 0.9 | 0.56 |
| Multiple system atrophy (MSA) | 0.3 | 0.3 | |
| myasthenia gravis | 0.4 | 0.4 | |
| neuropathic pain | 0.1 | -0.1 | |
| Neuropathy (all types) | 0.1 | 0.2 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 0.5 | 0.6 |
| NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
| Obesity | 1.2 | 1.3 | -0.08 |
| obsessive-compulsive disorder | 2.1 | 0.7 | 2 |
| Osteoarthritis | 1 | 0.2 | 4 |
| Osteoporosis | 0.4 | 0.2 | 1 |
| pancreatic cancer | 0.1 | 0.1 | 0 |
| Parkinson's Disease | 1.3 | 1.2 | 0.08 |
| Polycystic ovary syndrome | 1.7 | 0.2 | 7.5 |
| primary biliary cholangitis | 0.1 | 0.5 | -4 |
| Primary sclerosing cholangitis | 0.4 | 0.3 | 0.33 |
| Psoriasis | 0.8 | 0.5 | 0.6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.8 | -0.14 |
| Rosacea | 0 | 0 | |
| Schizophrenia | 0.6 | 0.1 | 5 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 0.4 | 0.7 | -0.75 |
| Sleep Apnea | 0.1 | 0.1 | 0 |
| Slow gastric motility / Gastroparesis | 0.4 | 0.4 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.6 | 0.1 | 5 |
| Systemic Lupus Erythematosus | 1.1 | 1.1 | |
| Tic Disorder | 0.7 | 0.7 | |
| Tourette syndrome | 0.1 | 0.1 | 0 |
| Type 1 Diabetes | 1.5 | 0.8 | 0.88 |
| Type 2 Diabetes | 2.7 | 2.3 | 0.17 |
| Ulcerative colitis | 2 | 1.7 | 0.18 |
| Unhealthy Ageing | 1.5 | 0.4 | 2.75 |
| Vitiligo | 0.5 | 0 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
